Newsroom

Sorted by: Latest
-

Mary Kay推出K-Beauty Texture Edit

達拉斯--(BUSINESS WIRE)--(美國商業資訊)-- 知名美妝巨擘Mary Kay Inc. 今日宣布推出K-Beauty Texture Edit， 該護膚系列限量發售，售完即止。該系列延續了於今年9月推出的Beauty Is More Beautiful Shared™（美，因分享而更美）的成功動力，這是公司針對消費者的規模最大的全球品牌平台。 K-Beauty Texture Edit旨在呼應在下一代消費者中蔚然成風的全球文化美妝潮流，其靈感源自韓國風靡全球的護膚與自我照護構想，主打豐富膚感、創新成分和升級的美妝體驗。這一緊跟趨勢的系列包含三款韓國製造產品：Mary Kay®融化卸妝膏(Melt-In Cleansing Balm)、Mary Kay®蝸牛凝膠臉部貼片(Snail Gel Face Patches)和Mary Kay®膠原保濕凝膠(Collagen Moisturizing Gel)。 隨著公司不斷擴大全球布局、觸達下一代美妝愛好者，並持續支援數十年來推動品牌走向成功的獨立美妝顧問和忠實客戶，此次發表代表Mary Kay持續演進過程中又一令人振奮的里程...
-

Mary Kay推出K-Beauty Texture Edit

达拉斯--(BUSINESS WIRE)--(美国商业资讯)-- 知名美妆巨头Mary Kay Inc. 今日宣布推出K-Beauty Texture Edit， 该护肤系列限量发售，售完即止。该系列延续了于今年9月推出的Beauty Is More Beautiful Shared™（美，因分享而更美）的成功势头，这是公司面向消费者的规模最大的全球品牌平台。 K-Beauty Texture Edit旨在呼应在新一代消费者中蔚然成风的全球文化美妆潮流，其灵感源自韩国风靡全球的护肤与自我护理理念，主打丰富肤感、创新成分和升级的美妆体验。这一紧跟趋势的系列包含三款韩国制造产品：Mary Kay®融化卸妆膏(Melt-In Cleansing Balm)、Mary Kay®蜗牛凝胶面膜贴(Snail Gel Face Patches)和Mary Kay®胶原保湿凝胶(Collagen Moisturizing Gel)。 随着公司不断拓展全球布局、触达新一代美妆爱好者，并持续支持数十年来推动品牌走向成功的独立美容顾问和忠实客户，此次发布标志着Mary Kay持续演进过程中又一令人振奋的里程...
-

Rosen Law Firm Urges Alphabet Inc. (NASDAQ: GOOGL, GOOG) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alphabet Inc. (NASDAQ: GOOGL, GOOG) between May 19, 2026 and July 16, 2026, inclusive (the “Class Period”). Alphabet is a technology company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating the Allegations that Alphabet Inc. (NASDAQ: GOOGL, GOOG) Mi...
-

Regulatory Affairs Partner Jeff Beelaert Joins Dorsey in Boise

BOISE, Idaho--(BUSINESS WIRE)--Jeff Beelaert has joined Dorsey & Whitney LLP as a Partner in the Firm’s Regulatory Affairs group in Boise, the international law firm announced today.Jeff's practice focuses on natural resources litigation, with particular emphasis on permit and project challenges. He represents clients in state and federal courts throughout the region and across the country. Jeff litigates novel and contested issues arising under environmental, energy, administrative, and con...
-

El simulador para entrenamiento de vuelo con realidad virtual Cessna Skyhawk Veris hará su debut en la feria NBAA-BACE en Las Vegas

TAMPA, Florida--(BUSINESS WIRE)--TRU Simulation + Training Inc., una empresa de Textron Inc. (NYSE:TXT) y filial de Textron Aviation, anunció hoy que su dispositivo de entrenamiento de vuelo (FTD) con realidad virtual Veris, configurado para el Cessna Skyhawk debutará en la Convención y Exposición de Aviación de Negocios de la Asociación Nacional de Aviación de Negocios (NBAA-BACE) de 2026. Este debut en la feria se suma al impulso generado en la NBAA-BACE 2025, donde TRU Simulation anunció un...
-

Italfarmaco and VeriSIM Life Partner to Develop Novel HDAC-Targeting Therapeutics for Neuromuscular, Fibrotic, and Rare Diseases

SAN FRANCISCO & MILAN--(BUSINESS WIRE)--Italfarmaco S.p.A., a global pharmaceutical company with established expertise in histone deacetylase (HDAC) biology and therapeutic development, and VeriSIM Life, an AI-enabled drug discovery and development company, today announced a strategic collaboration to discover and develop novel HDAC-targeted therapeutic assets for neuromuscular, fibrotic, and rare diseases.The collaboration brings together Italfarmaco’s expertise in HDAC biology, medicinal chemi...
-

Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, in combination with standard of care rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP), compared to R-CHOP alone, in newly diagnosed patients with diff...
-

Logistics Reply introduceert het LEA AI Agent Authority Model - waarmee beheerde agentic AI in Warehouse Execution wordt gebracht met LEA Dynamic Intelligence

TURIJN, Italië--(BUSINESS WIRE)--Logistics Reply, het bedrijf van de Reply Group gespecialiseerd in innovatieve oplossingen voor uitvoering van de toeleveringsketen en magazijnbeheer, onthulde vandaag het LEA AI Agent Authority Model, een nieuw praktisch kader dat samen met LEA Reply Dynamic Intelligence wordt geleverd, om organisaties in staat te stellen AI agents te integreren met de juiste bevoegdheid voor elke taak in plaats van maximale autonomie. Nu AI van ondersteuning naar live Warehous...
-

GOOG, GOOGL Class Action Notice: Alphabet Inc. Sued for Securities Fraud After Misstatements about AI Model Development Lead to 4% Stock Drop – Investors Urged to Contact BFA Law

NEW YORK--(BUSINESS WIRE)--Alphabet Inc. Sued for Securities Fraud After Misstatements about AI Model Development Lead to 4% Stock Drop – Investors Urged to Contact BFA Law...
-

The Living Legend Returns: No. 844 to Reunite with Big Boy for Holiday Tour

OMAHA, Neb.--(BUSINESS WIRE)--After a six-year hiatus, Union Pacific's Living Legend No. 844 is returning to the rails. The legendary steam locomotive will join Big Boy No. 4014 for Union Pacific's historic holiday tour this November, marking the first public appearance for No. 844 since the pair traveled together in 2019 to celebrate the 150th anniversary of the driving of the Golden Spike in Utah. The two steam locomotives will run as a “double header” during a fundraising excursion from Gree...